Dj Officer Breslin Acquires 340 Of Agree Realty Corp >Adc

Investing.com -- ADC Therapeutics SA (NYSE:ADCT) stock fell 22% Wednesday after the company released updated data from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with the bispecific antibody glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma.

The Switzerland-based antibody drug conjugate developer reported that the combination demonstrated an 89.8% overall response rate and a 77.6% complete response rate across 49 efficacy-evaluable patients with at least six months of follow-up. The company noted the combination continues to be "generally well-tolerated with a manageable safety profile."

Despite what appears to be positive efficacy data, investors reacted negatively to the update. The trial showed Grade 5 adverse events occurred in two patients (4.1%), with one being treatment-related according to the investigator. Additionally, cytokine release syndrome of all grades was observed in 36.7% of patients across dose levels.

Mohamed Zaki, Chief Medical Officer of ADC Therapeutics, highlighted the "manageable safety profile and strong efficacy including deep and durable responses" in the patient population. The company expects to complete enrollment of approximately 100 patients at the selected dose in the first half of 2026.

RBC Capital analyst Gregory Renza maintained an Outperform rating and $5.00 price target on ADC Therapeutics following the data release. "While there may be some considerations to keep in mind in the data such as deaths (not unusual in a DLBLC study) and variability in response across cuts -- and longer-term commercial questions may still linger -- we think the overall thrust of today’s update was positive, and should affirm a high likelihood of success and ultimate commercialization for the regimen," Renza commented.

The LOTIS-7 trial is evaluating ZYNLONTA in combination with glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- IDEAYA Biosciences Inc (NASDAQ:IDYA) stock rose 5.1% in Monday’s premarket trading after the company announced FDA clearance for its investigational new drug application for IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate.

The precision medicine oncology company plans to begin enrolling patients in a Phase 1 clinical trial in the first quarter of 2026. The study will initially evaluate patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers.

According to the Human Protein Atlas database, B7H3/PTK7 is co-expressed in lung, colorectal, and head and neck cancers at approximately 30%, 46%, and 27%, respectively. This co-expression pattern supports the potential for broad monotherapy activity.

"IND clearance for IDE034 is an important step in expanding our potential first-in-class TOP1 ADC clinical pipeline into bispecific, precision-guided approaches," said Darrin M. Beaupre, Chief Medical Officer of IDEAYA Biosciences.

Preclinical studies have shown strong anti-tumor activity in B7H3/PTK7-positive tumor models, including deep and durable tumor regressions with IDE034 monotherapy. The company also reported enhanced durability with IDE034 when combined with IDE161, IDEAYA’s PARG inhibitor, in preclinical in vivo models.

The company plans to share additional preclinical data supporting the mechanistic rationale for this combination at a medical conference in the first half of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.